WINTON GROUP Ltd Invests $972,000 in Tandem Diabetes Care, Inc. $TNDM

WINTON GROUP Ltd acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,244 shares of the medical device company’s stock, valued at approximately $972,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Royal Bank of Canada boosted its position in Tandem Diabetes Care by 30.5% during the first quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company’s stock valued at $4,054,000 after purchasing an additional 49,408 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Tandem Diabetes Care by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company’s stock valued at $1,426,000 after purchasing an additional 2,096 shares during the last quarter. Millennium Management LLC boosted its position in Tandem Diabetes Care by 41.1% during the first quarter. Millennium Management LLC now owns 227,585 shares of the medical device company’s stock valued at $4,361,000 after purchasing an additional 66,245 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Tandem Diabetes Care during the first quarter valued at approximately $225,000. Finally, Goldman Sachs Group Inc. boosted its position in Tandem Diabetes Care by 5.0% during the first quarter. Goldman Sachs Group Inc. now owns 712,559 shares of the medical device company’s stock valued at $13,653,000 after purchasing an additional 34,069 shares during the last quarter.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock opened at $17.61 on Wednesday. The stock’s fifty day moving average price is $17.92 and its two-hundred day moving average price is $20.34. Tandem Diabetes Care, Inc. has a one year low of $9.98 and a one year high of $29.65. The company has a debt-to-equity ratio of 4.54, a current ratio of 3.58 and a quick ratio of 3.07. The firm has a market cap of $1.21 billion, a PE ratio of -12.58 and a beta of 1.58.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.16. The firm had revenue of $247.22 million for the quarter, compared to the consensus estimate of $240.41 million. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The company’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.66) EPS. As a group, research analysts expect that Tandem Diabetes Care, Inc. will post -0.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TNDM. Barclays set a $55.00 price objective on Tandem Diabetes Care and gave the company an “overweight” rating in a research report on Monday, May 11th. Benchmark assumed coverage on Tandem Diabetes Care in a research report on Monday, May 11th. They issued a “hold” rating for the company. Mizuho set a $24.00 target price on Tandem Diabetes Care in a research note on Friday, May 8th. Citigroup reiterated a “neutral” rating and set a $17.00 target price (down from $22.00) on shares of Tandem Diabetes Care in a research note on Thursday, May 28th. Finally, Bank of America lowered their target price on Tandem Diabetes Care from $35.00 to $25.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and an average price target of $29.84.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.